CollPlant researchers created 3D tumor models using hydrogel-based microenvironments to study cancer responses to spatially targeted radiation.
Published
Signal category
Research & Knowledge
Quote
“Researchers created 3D tumor models to study how cancer responds to spatially targeted radiation.”
— Bowman Bagley|CollPlant team
Company
CollPlant
Pioneering Regenerative Medicine
- Industry
- Biotechnology Research
- Location
- Rehovot, IL
- Company size
- 48 employees
CollPlant is a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing. Our revolutionary plant-based technology is the only commercially viable technology for mass production of recombinant human Type I collagen (rhCollagen), which is identical to the collagen produced by the human body. This makes our rhCollagen the ideal building block for regenerative medicine. Leveraging on the unique properties of rhCollagen and biomaterial know-how, we are developing a pipeline of products aimed at 3D bioprinting of tissues and organs and medical aesthetics. Our mission at CollPlant is to deliver ground-breaking products for regenerative medicine that offer the optimal treatment options to patients.
Founded 2004